anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Children with functional constipation require prolonged laxative administration for proper emptying. Whether these laxatives can be weaned after better functioning is achieved is unknown. We aim to describe a standardized protocol for stimulant laxative weaning and its early outcomes.
METHODS: Patients were candidates for weaning if they had been on a stable laxative dose for six months, defined as one bowel movement per day with no soiling, impaction, or enemas. Laxative dose was decreased by 10-25% with re-evaluation every two weeks. If patients remained well without constipation, dose was weaned further by 10-25%. If there were worsening of symptoms, lower dose was maintained for 3-6 months until re-evaluation.
RESULTS: There were a total of sixteen patients evaluated. Median age was 12.7 years [IQR: 11.7-15.3] with laxative duration of 8.0 years [IQR: 5.4-10.7]. All patients were on senna; some were on fiber. Median starting senna dose was 71.3 mg [IQR: 54.3-75.0] and median fiber dose was 5.5 g [IQR: 4.0-6.0]. As of most recent follow up, nine patients (56.3%) had weaned off laxatives in 3.7 months [IQR: 1.3-11.6]. For those still on laxatives, median reduction in dose was 41.4 mg [30.0-75.0], and over half weaned their dose by >50%. Almost all (90.9%) of those on high doses were able to wean.
CONCLUSION: A standardized laxative weaning process can be successful in patients with functional constipation, especially on high doses. Further prospective studies will be necessary to confirm the success of this protocol.
LEVEL OF EVIDENCE: III.
To avoid confounding factors, we choose type 1 diabetic patients. We plan, with the data of literature a number need to be significative with a power of 80% and an Alpha risk at 5%, the inclusion of 160 patients for our primary analyze of p 22 phox. Those patients are included consequentially from the diabetic consultation of the university hospital of Grenoble, if they have a history of more than 20 years of diabetes. Those patients have been separated according to the existence of DN, and their polymorphism. Then we estimate with the Fisher test the prevalence of DN in risky patient, and the prevalence of the risky phenotype in the nephropathic patients. Then we investigate with the same statistical test the -429 T/C,he -374 T/A AGER and p.Arg261Gln 12 ALOX polymorphisms.
All enrollees will be health students at MUHAS recruited through announcements in class, flyers on student noticeboards, and email. Students who are interested in learning more about the study can do so by asking questions of the recruiting faculty member, by going to, telephoning, or emailing the study office (at MUHAS). Students can also visit the study website. In addition, all students who contact the office will be given a copy of a flyer advertising the study and a copy of the consent documents to preview prior to participation. Students contacting the office by email will be sent electronic versions of the same documents.

Participants in Aim 1 are informed to schedule an appointment (in the month prior to the seminar) to complete a pre-evaluation. At the study site, participants complete pen and paper surveys, and are videotaped interviewing two standardized patients. Next, participants are randomized to either the intervention or waitlist control condition. Participants in the intervention will attend the 4-day sexual health seminar and complete a short post-test. In addition, at 6- and 12-month follow-up after the pre-test, participants in both arms complete surveys and two videotaped interviews (at each follow-up) and a final survey at 24-month follow-up. At the end of the study, participants assigned to the control condition can attend the seminar.
Drug: Plamotamab will be administered at the target dose in addition to tafasitamab (12 mg/kg intravenously) plus lenalidomide (25 mg orally). This cohort was planned to enroll sequentially after Part 1A.
BACKGROUND: Haeme oxygenase (HO-1) affords protection against ischemia/reperfusion (I/R) injury; however, its effects on liver regeneration remain poorly explored. Our previous studies have shown that HO-1 is probably involved in liver regeneration, but its role in small-for-size syndrome (SFSS) is still unclear. Therefore, this study aims to investigate the effects of HO-1 on small-for-size graft (SFSG) and the underlying mechanism.
METHODS: Knockout of HO-1 rats by TALEN technique. Immunohistochemistry was used to detect HO-1 nuclear translocation. Haeme oxygenase activity was measured by detecting the amount of carbon monoxide (CO) generated from cell lysates. Flow cytometry was used to detect cell apoptosis and cell cycle. Western blot were performed to measure the expression level of HO-1 protein.
RESULTS: We identified that HO-1 was involved in SFSG regeneration; HO-1-knockout rats demonstrated significantly decreased liver proliferation and recovery. Interestingly, our results showed HO-1-induced SFSG regeneration was more likely to be the primary protector against SFSS than IRI. Furthermore, we verified the nuclear translocation of HO-1 and its protective effect on hypoxia/reoxygenation (H/R) damage in clone9 cells. Our results indicated that the HO-1 protein itself rather than heme breakdown metabolites might play a key role in liver regeneration.
CONCLUSIONS: The HO-1 protein itself rather than its metabolites possess a protective effect on small-for-size graft (SFSG) against SFSS via nuclear translocation.
FIELD: chemistry; medicine.SUBSTANCE: present invention relates to multicomponent microparticles for use in a composition for preventing and/or treating inflammatory or obstructive respiratory diseases. Each microparticle contains a combination of beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as active ingredients at ratio of 35:10:55 to 94:1:5 by weight. Method of producing said microparticles involves preparing a solution of three said active components in a solvent consisting of a mixture of ethanol and water in ratio of 85:15 to 95:5 by volume, forming an aerosol from the obtained solution and drying the sprayed droplets to form microparticles. Obtained microparticles are characterized by a shape factor from 0.95 to 1.05. Also described are a pharmaceutical aerosol composition for metered dose inhalers containing said microparticles in a suspension in a liquefied propellant gas, and a dry powder composition containing said microparticles and a carrier which is an alpha-lactose monohydrate in combination with magnesium stearate. Also described are a metered inhaler under pressure and a dry powder inhaler containing said pharmaceutical composition.EFFECT: microparticles according to the invention are characterized by homogeneous morphology and are stable for a long period of time.12 cl, 1 dwg, 7 tbl, 4 ex
The invention discloses an anti-hair-loss and hair-growing lotion which adopts green tea extract to improve blood circulation, promote the proliferation of human hair follicle papilla cells and prolong the cell cycle, thereby promoting the growth of hair. In addition, it can prevent testosterone from converting into dihydrotestosterone, and prevent alopecia caused by androgen excess. The disodium adenosine triphosphate has the function of improving the metabolism of the organism, participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotide in the body, and is also a source of energy in the body. The green tea extract can be used for assisting and strengthening the effect of promoting the proliferation of hair follicle hair papilla cells and promoting the growth of scalp hair follicles. The fleece-flower root and the Chinese arborvitae twig which contain trace element copper can stimulate the growth of hair follicles of scalp to make the hair grow more densely. Also discloses a preparation method of the hair restorer, which is simple and stable.
Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of "blocking ligands" to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.
A polypeptide present in normal human blood that interferes with the capacity of antigen presenting cells of the skin (Langerhans cells) to activate naive autologous T cells has been discovered and identified as the alpha-1 chain of the molecule haptoglobin. The haptoglobin alpha-1 chain is a selective inhibitor that acts only on antigen presenting cells and not on other cells of the immune system such as T lymphocytes. Therapeutic compositions containing human haptoglobin or its alpha-1 chain may be administered to a patient to interfere with Langerhans cells/dendritic cell-dependent activation of T cells and, therefore, to suppress T-cell dependent inflammation in vivo. Specific treatable inflammatory skin diseases include psoriasis, mycosis fungoidosis, atopic dermatitis, exfoliative dermatitis and Sezary's Syndrome. Other autoimmune, T cell dependent inflammations and infectious diseases would be treatable by the methods of the invention including prevention of transplant rejection (e.g. Graft Versus Host Disease), vaccine development, and therapy for infectious diseases where antigen presenting cells play a central role in the pathogenesis.
In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 30, 100, or 300 mg/kg/day crisaborole were administered to rats once daily. A crisaborole-related increased incidence of benign granular cell tumors in the uterus with cervix and vagina (combined) was noted in 300 mg/kg/day crisaborole treated female rats (2 times the MRHD on an AUC comparison basis). The clinical relevance of this finding is unknown.

In a dermal carcinogenicity study in CD-1 mice, topical doses of 2%, 5%, or 7% crisaborole ointment were administered once daily. No crisaborole-related neoplastic findings were noted at topical doses up to 7% crisaborole ointment (1 times the MRHD on an AUC comparison basis).

Crisaborole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay). 

No effects on fertility were observed in male or female rats that were administered oral doses up to 600 mg/kg/day crisaborole (13 times the MRHD on an AUC comparison basis) prior to and during early pregnancy.
Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillacea). It has a potency of not less than 6000 polymyxin B units per mg, calculated on the anhydrous basis. The structural formulae are: 

Each vial contains 500,000 polymyxin B units for parenteral or ophthalmic administration. 

Polymyxin B for Injection, USP is in powder form suitable for preparation of sterile solutions for intramuscular, intravenous drip, intrathecal, or ophthalmic use. In the medical literature, dosages have frequently been given in terms of equivalent weights of pure polymyxin B base. Each milligram of pure polymyxin B base is equivalent to 10,000 units of polymyxin B and each microgram of pure polymyxin B base is equivalent to 10 units of polymyxin B. 

Aqueous solutions of polymyxin B sulfate may be stored up to 12 months without significant loss of potency if kept under refrigeration. In the interest of safety, solutions for parenteral use should be stored under refrigeration and any unused portion should be discarded after 72 hours. Polymyxin B sulfate should not be stored in alkaline solutions since they are less stable.
Administration of hydroxychloroquine sulfate to patients with porphyria may exacerbate porphyria. Avoid hydroxychloroquine sulfate in patients with porphyria.

Hepatotoxicity Associated with Porphyria Cutanea Tarda

Cases of hepatotoxicity have been reported when hydroxychloroquine was used in patients with porphyria cutanea tarda (PCT). Patients received dosages ranging from 200 mg twice weekly to 400 mg daily. Most of the PCT-related cases presented with marked elevations in transaminases (>20 times upper limit of the reference range) within days to a month of hydroxychloroquine initiation. In some cases, PCT was diagnosed only after the occurrence of treatment-induced liver injury, when hydroxychloroquine was prescribed for an approved indication. Some of the cases were associated with other risk factors for hepatic injury (e.g., alcohol use, concomitant hepatotoxic medications).

Measure liver tests promptly in patients who report symptoms that may indicate liver injury, such as fatigue, rash, nausea, dark urine, or jaundice. In this clinical context, if the patient is found to have abnormal serum liver tests (e.g., ALT level greater than three times the upper limit of the reference range, total bilirubin greater than two times the upper limit of the reference range), interrupt treatment with hydroxychloroquine sulfate, and investigate further to establish the probable cause.

The safety and effectiveness of hydroxychloroquine sulfate for the treatment of PCT have not been established and hydroxychloroquine sulfate is not approved for this use.
Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
Starting on Day 1 of each 21-day cycle, participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) for up to 35 cycles (approximately 2 years), plus 160 mg enzalutamide taken orally once daily, while maintaining continuous ADT with a luteinizing-hormone releasing hormone (LHRH) agonist or antagonist during study treatment. Participants will continue to receive enzalutamide and ADT until criteria for discontinuation are met.
Background. Sexual and gender minority (SGM) youth account for the largest number of incident HIV infections in Brazil. Although HIV can be managed with ongoing antiretroviral therapy (ART), exceptionally high levels of adherence are required. Brazil has implemented a comprehensive HIV treatment program with broad access to ART, but this program does not specifically address barriers to optimal ART adherence, particularly for SGM youth who experience many challenges taking their medication as prescribed. Overview. This application seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among HIV infected SGM youth (ages 15-24) in Rio de Janeiro, Brazil. The intervention aims to improve social support, self-efficacy for taking ART, and teach skills for problem-solving barriers to promote better adherence. To inform the content, structure, and format of the proposed intervention, the MPIs recently conducted focus groups with SGM youth (N = 18) and key informant interviews (N = 7) with medical providers and staff at local HIV service organizations working closely with SGM youth in Rio de Janeiro. Across focus groups and key informant interviews there was universal agreement that an intervention should capitalize on and enhance social support structures among SGM youth, and address their specific concerns, especially as related to the individual (e.g., ART side effects, mood, substance use), social (e.g., HIV/SGM stigma), and structural (e.g., clinic hours, transportation challenges) barriers that they regularly face. Theoretical Model. The intervention is guided by Social Cognitive and Social Support Theories and is grounded in the social and contextual realities of SGM youth living with HIV in Brazil. Specifically, social support is emphasized and informational, problem-solving and cognitive-behavioral "steps" are addressed over 4-group adherence counseling sessions, which include short video vignettes that seek to normalize adherence challenges. In addition, daily tailored SMS text messages are delivered as part of the intervention to facilitate social-cognitive cues to take medications as prescribed. Research Plan. Phase 1: Refine and enhance participant acceptability of the intervention and resolve any issues with intervention delivery/implementation; this will be achieved by convening and obtaining feedback from our youth community advisory board throughout this phase and subsequent phases; and by conducting an open-phase pilot with up to 12 SGM youth, with post-intervention exit interviews, as well as obtaining feedback from our youth community advisory board throughout this and subsequent phases. Phase 2: Examine, in a pilot randomized controlled trial, the feasibility, acceptability and potential impact of the proposed intervention among approximately 72 SGM youth who will be equally randomized to the intervention or a standard of care control condition with standard of care. The outcomes are improved ART adherence, retention in care and viral load suppression. Study assessments will be conducted at baseline, 3- and 6-months.
BACKGROUND: Epilepsy and other seizure disorders account for a high disease burden in Germany. As a timely diagnosis and accurate treatment are crucial, improving the management of these disorders is important. Outside of Germany, outpatient long-term video EEGs (ALVEEGs) have demonstrated the potential to support the diagnosis and management of epilepsy and other seizure disorders. This study aims to evaluate the implementation of ALVEEGs as a new diagnostic pathway in eastern parts of Germany to diagnose epilepsy and other seizure disorders and to assess if ALVEEGs are equally effective as the current inpatient-monitoring gold standard, which is currently only available at a limited number of specialized centers in Germany.
METHODS: ALVEEG is a prospective, multicenter, randomized controlled equivalence trial, involving five epilepsy centers in the eastern states of Germany. Patients will be randomized into either intervention (IG) or control group (CG), using a permuted block randomization. The sample size targeted is 688 patients, continuously recruited over the trial. The IG will complete an ALVEEG in a home setting, including getting access to a smartphone app to document seizure activity. The CG will receive care as usual, i.e., inpatient long-term video-EEG monitoring. The primary outcome is the proportion of clinical questions being solved in the IG compared to the CG. Secondary outcomes include hospital stays, time until video EEG, time until diagnosis and result discussion, patients' health status, quality of life and health competence, and number and form of epilepsy-related events and epileptiform activity. Alongside the trial, a process implementation and health economic evaluation will be conducted.
DISCUSSION: The extensive evaluation of this study, including an implementation and health economic evaluation, will provide valuable information for health policy decision-makers to optimize future delivery of neurological care to patients affected by epilepsy and other seizure disorders and on the uptake of ALVEEG into standard care in Germany.
TRIAL REGISTRATION: German Clinical Trials Register (DRKS00032220), date registered: December 11, 2023.
Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
PROBLEM TO BE SOLVED: To provide a new substance having interleukin 1β conversion enzyme inhibiting action and sphingomyelinase inhibiting action and useful for the treatment of rheumatoid arthritis, etc. SOLUTION: The objective compound is expressed by formula I, preferably formula II. The compound of formula I or II can be produced by culturing a microorganism belonging to the genus Trichoderma and capable of producing the compound of formula I or formula II (e.g. FERM P-16787) in a medium, accumulating the cultured product and collecting the objective compound from the cultured product. The compound has the following physical and chemical properties: nature, pale yellow amorphous powder; molecular weight, 174; molecular formula, C7 H10 O6 ; specific rotation, [α]D<20> =28 deg. (c=0.1, in water); solubility in solvents, soluble in water and dimethyl sulfoxide, scarcely soluble in ethanol, ethyl acetate and chloroform; color reactions, positive to sulfuric acid and phosphomolybdic acid, negative to ninhydrin and Dragendorff reaction; etc.
Patients with work-related stress (diagnoses F43.2/8/9 or Z56.3 (ICD-10)) who was seen at a consultation at Department of Occupational and Environmental Health in Odense (DOEM) in 2011-2012, but did not receive the intervention because it was not yet offered. The patients were offered advice and support by a psychologist (usual care). The intervention was introduced at DOEM in 2011 for a limited number of patients due to introducing the intervention and establishing the capacity of psychologists involved. In 2013 the intervention was implemented at full scale to include every eligible patient.
A cognitive evaluation and a Digital Diagnostic (DD) session performed anytime before radiotherapy will serve as the baseline. After the radiotherapy treatment, which can last between 1 to 6.5 weeks, patients will have a variable recovery time (0 to 4 weeks). Subsequently, patients will be subject to a cognitive evaluation and a DD session, right before starting the Digital Intervention (DI) training. This training will comprise ten weeks of DI (three 10-15 minute sessions per week). Patients will complete cognitive evaluations and DD sessions at the end of DI, and 16 and 32 weeks after the end of DI.